

## Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff

Published: 2007-SEP-26

Pages: 277

Format: PDF

Price: 7600 USD

### Description

#### Introduction

This report provides a comprehensive strategic analysis of the mAb market out to 2012 by company. It identifies four 'established' and four 'emerging' players within the mAb sector which are forecast to play the most commercially significant role within this market. The report assesses how these players will be insulated from the impact of generic competition as a result of mAb market penetration.

#### Scope

Provides in-depth analysis (including sales forecasts to 2012) of key players within the mAb market. Assesses the strategic decisions which have been implemented by key mAb market players. Provides an overview of mAb market business models and alliance networks. Outlines the key therapeutic segments within the mAb market where key players operate.

#### Highlights

Over the period 2006-12, monoclonal antibodies (mAbs) are forecast to act as the key growth segment of the prescription pharmaceutical market. mAb revenues are anticipated to grow at a compound annual growth rate of 14.2% over the period 2006-12, versus 2.2% for the overall market. Four players currently hold a dominant position in the global mAb market: Genentech, Roche, Johnson & Johnson and Abbott, accounting for a combined 74.8% share of mAb market revenues. However, Datamonitor forecasts that by 2012 a number of additional players will have significantly enhanced their presence in the mAb segment, with four companies Biogen IDEC, Amgen, Novartis and UCB Pharma each forecast to generate mAb sales growth in excess of \$1 billion.

#### Reasons to Purchase

Understand in detail the dynamics of mAb market growth over 2006-12, which will be driven by four 'established' players and four 'emerging' players. Assess how penetration of the mAb market will provide companies with increased insulation from the impact of generic competition. Analyze the factors that have driven the evolution and commercial expansion of the mAb market, and those that will drive future sales growth.

### Table of Contents

About the PharmaVitae team 3

Scope of the report 4

CHAPTER 1 EXECUTIVE SUMMARY 5

Key findings 5

Total market outlook 5

Monoclonal antibody market outlook 6

Introduction to the PharmaVitae universe 8

Prescription pharmaceutical market performance, 2006-12 10

Generic competition and the 'patent cliff' - the key driver of market growth 11

Balance of launch and expiry products in the prescription pharmaceutical market, 2006-12 11

The majority of expiry driven sales decline occurs over the 'patent cliff' 13

Prescription pharmaceutical sales by molecule type, 2006-12 14

Generic competition and the 'patent cliff' - an exclusive burden on small molecules 15

Absolute annual sales growth by molecule type, 2006-12 16

Sales growth rate by molecule type, 2006-12 17

mAb market performance 2006-12 18

mAbs are the most attractive product segment in the prescription pharmaceutical market, 2006-12 19

# BioMarket Group - A Global Online Aggregator of Life Science Market Research

Contrasting fortunes - Roche versus Pfizer	20
mAb market penetration - insulation from the 'patent cliff'	21
Which companies have the mAbs?	25
Established mAb players	27
The role of Big Pharma	28
The 'Big 5' products	32
Genentech & Roche	34
Johnson & Johnson	38
Abbott	41
Strategies of the four incumbent players	42
Emerging mAb players	44
Emergent biotech players have gained scale	45
The need to circumvent the 'Big 5' products	45
Direct head-to-head competition	47
Position as complementary therapy to incumbent mAb	47
Access patients who are refractory to gold-standard therapy	48
Biogen IDEC	52
Amgen	54
Novartis	56
UCB Pharma	57
CHAPTER 2 MAB COMPANY ANALYSIS	62
Key findings	62
The monoclonal antibody business model	64
mAb technology providers	65
Early-stage mAb developers	66
Late-stage mAb developers	67
Fully-integrated companies	68
Case study: PDL BioPharma	70
mAb alliance network	73
Early-stage alliances	73
Late-stage alliances	74
mAb driven M&A activity	75
Key players in the mAb market	79
Historical mAb company landscape	82
Forecast mAb company landscape	84
mAb sales dependency	87
Therapeutic focus	91
Oncology mAb market	92
AIID mAb market	95
Other mAb market	97
Technology focus	99
Pipeline focus	103
Emerging mAb technology providers	106
Private company overview	106
mAb company profiles	111
CHAPTER 3 ROCHE/GENENTECH	113
Introduction	113
Genentech partnership gives Roche mAb market superiority	113
Global licensing of Genentech products	114
The emergence of an oncology giant	115
mAb SWOT	116
mAb alliances	120
Financial position	122
Historical sales performance	123
Forecast sales performance	126
mAb portfolio	130
Avastin (bevacizumab)	131
Overview	131
Current market assessment	131
Future market assessment	132
Rituxan (rituximab)	132
Overview	132
Current market assessment	133
Future market assessment	134
Herceptin (trastuzumab)	134
Overview	134
Current market assessment	135
Future market assessment	135
Lucentis (ranibizumab)	136
Overview	136
Current market assessment	137
Future market assessment	138
Xolair (omalizumab)	138
Overview	138
Current market assessment	139
Future market assessment	140

# BioMarket Group - A Global Online Aggregator of Life Science Market Research

Raptiva (efalizumab) 141
Overview 141
Current market assessment 141
Future market assessment 143
Actemra (tocilizumab) 143
Overview 143
Current market assessment 144
Future market assessment 145
Zenapax (daclizumab) 145
Overview 145
Current market assessment 146
Future market assessment 146
mAb pipeline 147
CHAPTER 4 JOHNSON & JOHNSON 149
Introduction 149
Acquisition of Centocor central to J&J's antibody presence 149
mAb SWOT 152
mAb alliances 153
Financial position 154
Historical sales performance 155
Forecast sales performance 157
mAb portfolio 160
Remicade (infliximab) 161
Overview 161
Current market assessment 161
Future market assessment 163
Reopro (abciximab) 163
Current market assessment 164
Future market assessment 164
mAb pipeline 165
Golimumab 166
Overview 166
Future market assessment 166
CHAPTER 5 ABBOTT LABORATORIES 168
Introduction 168
In-licensing strategy secures Abbott's mAb position 168
Humira central to Abbott's growth in the wake of core genericization 169
mAb alliances 171
Financial position 172
Historical sales performance 173
Forecast sales performance 175
mAb portfolio 178
Humira (adalimumab) 178
Overview 178
Current market assessment 180
Future market assessment 181
Synagis (palivizumab) 182
Overview 182
Current market assessment 183
Future market assessment 183
mAb pipeline 183
Numax (motavizumab) 184
Overview 184
Future market assessment 186
CHAPTER 6 UCB PHARMA 187
Introduction 187
Celltech innovation to drive long-term opportunity 188
Cimzia central to UCB's medium-term accretion from Celltech acquisition 189
mAb SWOT 190
mAb alliances 191
Financial position 192
Historical sales performance 193
Forecast sales performance 194
mAb pipeline 197
Cimzia (certolizumab pegol) 198
Overview 198
Future market assessment 198
LymphoCide (epratuzumab) 199
Overview 199
Future market assessment 200
CHAPTER 7 BIOGEN IDEC 201
Introduction 201
mAb platform supported by manufacturing and development infrastructure 201
Tysabri central to medium-term growth potential 203
mAb SWOT 204
mAb alliances 205

# BioMarket Group - A Global Online Aggregator of Life Science Market Research

Financial position	206
Historical sales performance	207
Forecast sales performance	208
mAb portfolio	211
Tysabri (natalizumab)	212
Overview	212
Current market assessment	213
Future market assessment	214
Rituxan (rituximab)	214
mAb pipeline	215
Galiximab (anti-CD80)	216
Lumiliximab (anti-CD23)	217
Daclizumab (anti-CD25)	217
Volociximab (anti-AAB1)	218
CHAPTER 8 AMGEN	219
Introduction	219
Abgenix integration diversifies Amgen's robust molecule focus	219
mAb SWOT	221
mAb alliances	222
Financial position	223
Historical sales performance	224
Forecast sales performance	225
mAb portfolio	229
Vectibix (panitumumab)	229
Overview	229
Current market assessment	230
Future market assessment	230
mAb pipeline	231
Denosumab	233
Overview	233
Future market assessment	233
AMG 531 (anti-MGDF)	234
Overview	234
Future market assessment	234
CHAPTER 9 NOVARTIS	235
Introduction	235
Externalization pursuits provide Novartis with mAb opportunity	235
mAb SWOT	237
mAb alliances	238
Financial position	239
Historical sales performance	240
Forecast sales performance	242
mAb portfolio	245
Xolair (omalizumab)	245
Lucentis (ranibizumab)	245
mAb pipeline	246
Mycograb (efungumab)	247
Future market assessment	248
CHAPTER 10 MEDIMMUNE	249
Introduction	249
mAb SWOT	251
mAb alliances	252
Financial position	253
Historical sales performance	254
Forecast sales performance	256
mAb portfolio	259
Synagis (palivizumab)	259
Overview	259
Current market assessment	259
Future market assessment	260
mAb pipeline	260
Numax (motavizumab)	262
Overview	262
Future market assessment	262
CHAPTER 11 APPENDIX	263
References	263
Abbreviations	263
List of Tables	
Table 1: PharmaVitae company coverage by peer set	8
Table 2: Forecast sales by molecule type (\$m), 2006-12	14
Table 3: mAb market overview, sales (\$m), 2003-12	25
Table 4: Sales (\$m) of 'top 4' mAb players in 2003, 2006 and 2012	27
Table 5: Key examples of mAb-fuelled M&A	75
Table 6: mAb market overview, sales (\$m), 2003-12	79
Table 7: Oncology mAb market sales (\$m) by company, 2006 and 2012	92
Table 8: AIID mAb landscape, sales (\$m), 2006 and 2012	95

# BioMarket Group - A Global Online Aggregator of Life Science Market Research

Table 9: Other TAs mAb landscape, sales (\$m), 2006 and 2012	97
Table 10: Technology presence by company, marketed mAbs in 2012	101
Table 11: mAb pipeline by company, preclinical to launched	103
Table 12: Private mAb company landscape	107
Table 13: mAb company profiles, sales (\$m)	111
Table 14: Roche/Genentech's operating revenue/cost analysis (\$m), 2003-06	122
Table 15: Roche/Genentech's historical performance, sales (\$m), 2003-06	123
Table 16: Roche/Genentech's forecast performance, sales (\$m), 2006-12	126
Table 17: Roche/Genentech marketed mAb portfolio	130
Table 18: Roche/Genentech's mAb pipeline (Phase I-III)	147
Table 19: J&J's operating revenue/cost analysis (\$m), 2003-06	154
Table 20: J&J's historical performance, sales (\$m), 2003-06	155
Table 21: J&J's forecast performance, sales (\$m), 2006-12	157
Table 22: J&J's mAb portfolio	161
Table 23: J&J's mAb pipeline	165
Table 24: Abbott's operating revenue/cost analysis (\$m), 2003-06	172
Table 25: Abbott's historical performance, sales (\$m), 2003-06	173
Table 26: Abbott's forecast performance, sales (\$m), 2006-12	175
Table 27: Abbott's mAb portfolio	178
Table 28: Abbott's mAb pipeline	183
Table 29: UCB's operating revenue/cost analysis (\$m), 2003-06	192
Table 30: UCB's historical performance, sales (\$m), 2003-06	193
Table 31: UCB's forecast performance, sales (\$m), 2006-12	194
Table 32: UCB's mAb pipeline	197
Table 33: Biogen Idec's operating revenue/cost analysis (\$m), 2003-06	206
Table 34: Biogen Idec's historical performance, sales (\$m), 2003-06	207
Table 35: Biogen Idec's forecast performance, sales (\$m), 2006-12	208
Table 36: Biogen Idec's marketed mAb portfolio	212
Table 37: Biogen Idec's mAb pipeline	215
Table 38: Amgen's operating revenue/cost analysis (\$m), 2003-06	223
Table 39: Amgen's historical performance, sales (\$m), 2003-06	224
Table 40: Amgen's forecast performance, sales (\$m), 2006-12	225
Table 41: Amgen's marketed mAb portfolio	229
Table 42: Amgen's mAb pipeline	231
Table 43: Novartis's operating revenue/cost analysis (\$m), 2003-06	239
Table 44: Novartis's historical performance, sales (\$m), 2003-06	240
Table 45: Novartis's forecast performance, sales (\$m), 2006-12	242
Table 46: Novartis's mAb portfolio	245
Table 47: Novartis's mAb pipeline	246
Table 48: MedImmune's operating revenue/cost analysis (\$m), 2003-06	253
Table 49: MedImmune's historical performance, sales (\$m), 2003-06	254
Table 50: MedImmune's forecast performance, sales (\$m), 2006-12	256
Table 51: Abbott's mAb portfolio	259
Table 52: MedImmune's mAb pipeline	260

## List of Figures

Figure 1: Pharmaceutical market performance, sales (\$m) and year-on-year growth (%), 2006-12	10
Figure 2: Sales growth by launch, core & expiry (ethical sales \$m), 2006-12	12
Figure 3: Expiry portfolio, year-on-year change in annual sales (\$m), 2006-12	13
Figure 4: Forecast sales by molecule type (\$m), 2006-12	15
Figure 5: Change in annual sales (\$m) by molecule type, 2006-12	16
Figure 6: Sales compound annual growth rate (CAGR) by molecule type, 2006-12	17
Figure 7: mAb market outlook, sales (\$m) and year-on-year growth (%), 2006-12	18
Figure 8: Top five PV growth drivers & resistors, sales (\$m), 2006-12	21
Figure 9: Absolute growth by company, sales (\$m), 2011-12	23
Figure 10: Percentage growth by molecule type, 2011-12	24
Figure 11: mAb sales by company, 2006-12 (US\$m)	26
Figure 12: The established mAb players - absolute annual sales growth (\$m), 2006-12	28
Figure 13: Dominance of the 'Big 5' mAb products - The 'big 5' mAbs have held over 70% of mAb sales since 2003 and are forecast to retain this market dominance until 2012	33
Figure 14: Genentech/Roche absolute sales growth by molecule type, (\$m) 2006-12	34
Figure 15: J&J's absolute growth by molecule type, sales (\$m), 2006-12	38
Figure 16: Abbott's absolute growth by molecule type, sales (\$m), 2006-12	41
Figure 17: The emerging mAb players - absolute annual sales growth (\$m), 2006-12	44
Figure 18: Dominance of oncology and AIID in mAb market - mAb absolute annual sales growth (\$m), 2006-12	46
Figure 19: Biogen IDEC's absolute growth by molecule type, sales (\$m), 2006-12	52
Figure 20: Amgen's absolute growth by molecule type, sales (\$m), 2006-12	54
Figure 21: Novartis's absolute growth by molecule type, sales (\$m), 2006-12	56
Figure 22: UCB's absolute growth by molecule type, sales (\$m), 2006-12	57
Figure 23: mAb company evolution	65
Figure 24: Examples of company placement across the mAb business model	70
Figure 25: Major factors motivating mAb-fuelled acquisition	78
Figure 26: mAb sales by company (\$m), 2003, 2006 and 2012	81
Figure 27: mAb sales by company (\$m), 2003-06	82
Figure 28: Absolute mAb sales growth (\$m), 2003-06	83
Figure 29: mAb market outlook (\$m), 2006-12	84
Figure 30: mAb sales by company (\$m), 2006-12	85

## BioMarket Group - A Global Online Aggregator of Life Science Market Research

Figure 31: Absolute mAb sales growth (\$m), 2006-12 86  
Figure 32: mAb sales dependency (%), 2006 88  
Figure 33: mAb sales dependency (%), 2012 89  
Figure 34: mAb landscape by therapy area, 2006-12 91  
Figure 35: Oncology mAb landscape, 2006 and 2012 94  
Figure 36: AIID mAb landscape, 2006-12 97  
Figure 37: Other mAb landscape, 2006-12 99  
Figure 38: Technology presence by company, marketed mAbs in 2012 102  
Figure 39: mAb programs by company, preclinical to launched 104  
Figure 40: No. of commercial and institutional collaborations, circle size corresponds to no. of mAb programs 109  
Figure 41: SWOT analysis of Roche/Genentech 116  
Figure 42: Genentech (and Roche) major mAb alliances 120  
Figure 43: Roche/Genentech mAb vs. non-mAb sales (\$m), 2003-06 125  
Figure 44: Roche/Genentech mAb vs. non-mAb sales (\$m), 2006-12 127  
Figure 45: Roche/Genentech consolidated mAb product sales (\$m), ~ 2006-12 128  
Figure 46: J&J's SWOT analysis 152  
Figure 47: J&J's major mAb alliances, past and present 153  
Figure 48: J&J's mAb vs. non-mAb sales (\$m), 2003-06 156  
Figure 49: J&J's mAb vs. non-mAb sales (\$m), 2006-12 159  
Figure 50: J&J's mAb product sales (\$m), 2006-12 160  
Figure 51: Abbott's mAb SWOT analysis 170  
Figure 52: Abbott's major mAb alliances, past and present 171  
Figure 53: Abbott's mAb vs. non-mAb sales (\$m), 2003-06 174  
Figure 54: Abbott's mAb vs. non-mAb sales (\$m), 2006-12 176  
Figure 55: Abbott's mAb product sales (\$m), 2006-12 177  
Figure 56: UCB's SWOT analysis 190  
Figure 57: UCB's major mAb alliances, past and present 191  
Figure 58: UCB's mAb vs. non-mAb sales (\$m), 2006-12 195  
Figure 59: UCB's mAb product sales (\$m), 2006-12 196  
Figure 60: Biogen Idec's SWOT analysis 204  
Figure 61: Biogen Idec's major mAb alliances, past and present 205  
Figure 62: Biogen Idec's mAb vs. non-mAb sales (\$m), 2006-12 210  
Figure 63: Biogen Idec's mAb product sales (\$m), 2006-12 211  
Figure 64: Amgen's SWOT analysis 221  
Figure 65: Amgen's major mAb alliances, past and present 222  
Figure 66: Amgen's mAb vs. non-mAb sales (\$m), 2006-12 226  
Figure 67: Amgen's mAb product sales (\$m), 2006-12 227  
Figure 68: Novartis's SWOT analysis 237  
Figure 69: Novartis's major mAb alliances, past and present 238  
Figure 70: Novartis's mAb vs. non-mAb sales (\$m), 2003-06 241  
Figure 71: Novartis's mAb vs. non-mAb sales (\$m), 2006-12 243  
Figure 72: Novartis's mAb product sales (\$m), 2006-12 244  
Figure 73: MedImmune's SWOT analysis 251  
Figure 74: MedImmune's major mAb alliances, past and present 252  
Figure 75: MedImmune's mAb vs. non-mAb sales (\$m), 2003-06 255  
Figure 76: MedImmune's mAb vs. non-mAb sales (\$m), 2006-12 257  
Figure 77: MedImmune's mAb product sales (\$m), 2006-12 258

### Ordering

Order Online - <http://www.biomarketgroup.com/market-research-report/monoclonal-antibodies-report-part-ii-companies-holding-mabs-in-portfolio-promises-protection-against-the-looming-2011-12-patent-cliff.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioMarket Group  
Björnnäsvägen 21  
11419 STOCKHOLM

## Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit <http://www.biomarketgroup.com/index.php/contacts/>

### Order Information

Please verify that the product information is correct:

Product Name: **Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff**

Web Address: <http://www.biomarketgroup.com/market-research-report/monoclonal-antibodies-report-part-ii-companies-holding-mabs-in-portfolio-promises-protection-against-the-looming-2011-12-patent-cliff.html>

Format: PDF

Price: 7600 USD (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD.

### Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: \_\_\_\_\_

Name: \_\_\_\_\_

Email Address:\* \_\_\_\_\_

Job Title: \_\_\_\_\_

Organization: \_\_\_\_\_

EU companies must supply: VAT / BTW / MOMS  
MWST / IVA / FPA number:  
\_\_\_\_\_

Address: \_\_\_\_\_

Zip Code: \_\_\_\_\_

City: \_\_\_\_\_

State: \_\_\_\_\_

Country: \_\_\_\_\_

Phone Number: \_\_\_\_\_

Fax Number: \_\_\_\_\_

### Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:**
- American Express
  - Master Card
  - Visa

Cardholder Name: \_\_\_\_\_

Expiry Date (MM/YY): \_\_\_\_\_

Card Number: \_\_\_\_\_

CVV Number: \_\_\_\_\_

- Pay by check:**

Please post the check, accompanied by this form, to:  
BioMarket Group  
Björnnäsvägen 21  
11419 STOCKHOLM  
SWEDEN

- Pay by wire transfer:** Please transfer funds to:

Account number: 43521169  
Swift code: HANDSESS  
IBAN number: SE74 6000 0000 0000 4352 1169  
Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:  
Marketing Code: \_\_\_\_\_

Please supply purchase order number if needed:  
\_\_\_\_\_

\* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at <http://www.biomarketgroup.com/index.php/biomarket-group-full-terms-and-conditions>

**Please fax this form to: +46-8-56849191**